For men with aggressive prostate cancer, hormone-targeted therapy cuts the overall risk of death, according to a new review of past studies.
It also does not increase the chance that men will die from cardiovascular disease -- which some research had suggested might be the case.
So-called androgen deprivation therapy, or ADT, has been the standard of treatment for men with more aggressive, high-risk prostate cancers. The drugs suppress the body's production of testosterone, which is known to speed cancer growth.
But they've also been linked to side effects including hot flashes, weight gain, diabetes and loss of sex drive -- and, more recently, to cardiovascular risks. One recent study linked hormone-targeted therapy to an increased risk of blood clots.
Read more here:
